WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today commented on reports that the Securities and Exchange Commission (SEC) will begin the process of easing auditing standards for small, publicly traded companies. Earlier this year, a BIO-led coalition called for scaled reforms to Section 404 of Sarbanes-Oxley to provide smaller public companies relief from costly Section 404 requirements:
